Plus   Neg

UBS Q1 Profit Up 40%

Swiss banking giant UBS Group AG (UBS) Tuesday reported a growth in its profit for the first quarter, driven by strong performances across all businesses, with a double digit growth in net interest income.

The Group's net profit attributable to shareholders rose 40 percent to $1.595 billion and earnings per share grew 43 percent to 43 cents. Profit before tax grew 30 percent year-on-year.

Operating income for the period grew by 10 percent to $7.93 billion, despite a rise in credit loss expenses, the Group said. However, operating expenses during the quarter increased by 4 percent.

Return on CET1 capital or RoCET1 was 17.7 percent, compared to 13.3 percent last year. The Group also reported CET1 capital ratio of 12.8 percent; CET1 leverage ratio of 3.8 percent; and tier 1 leverage ratio of 5.4 percent, all excluding any regulatory relief.

The Group's net interest income for the quarter rose 18 percent to $1.33 billion, and Fee and commission income rose 21 percent to $5.48 billion.

Looking ahead, the Group said the disruption to businesses and rising unemployment caused by the corona pandemic will result in elevated levels of loan losses to the industry.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT